FBLG News & Events

The net loss for the three months ended March 31, 2026, was primarily due to research and development expenses and general and administrative expenses. Pete O'Heeron, CEO, and Founder of FibroBiologics commented, "During the first quarter of 2026, we made important progress initiating our phase 1/2 clinical trial, including completing cGMP manufacturing of the first batch of the CYWC628 drug product and site onboarding to support dosing the first patient in the second quarter. We continued to build momentum across our pipeline, with positive preclinical data in both our burn and degenerative disc disease programs, further supporting the potential of our fibroblast-based platform. We also strengthened our cash position with additional capital. As we move into the next phase of execution, our focus is on initiating our clinical study, generating meaningful data, and advancing our pipeline programs in psoriasis and multiple sclerosis."

FibroBiologics announced that The Nasdaq Stock Market has confirmed that the company has demonstrated compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $2.5M stockholders' equity requirement and the $1.00 bid price requirement. The company has now successfully resolved its Nasdaq compliance issues but will remain subject to one-year monitoring periods for both stockholders' equity and bid price compliance.

FibroBiologics announced the pricing of a best efforts public offering of an aggregate of 2,272,728 shares of its common stock and warrants to purchase up to 2,272,728 shares of common stock, at a combined public offering price of $1.32 per share and accompanying Warrant. The Warrants will have an exercise price of $1.32 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Warrants and will expire on the five-year anniversary of the date of Stockholder Approval. The closing of the offering is expected to occur on or about April 2, 2026, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.